FindTrial
Sign In

Randomized control trial on the effects of rifaximin and midodrine combined with standard diuretic therapy versus midodrine with standard diuretic therapy in chronic liver disease patients with refractory ascites in a tertiary hospital

Randomized control trial on the effects of rifaximin and midodrine combined with standard diuretic therapy versus midodrine with standard diuretic therapy in chronic liver disease patients with refractory ascites - NA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104411
Enrollment
100
Registered
2026-02-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R188- Other ascites

Interventions

Intervention1: Randomized control trial on the effects of rifaximin and midodrine combined with standard diuretic therapy versus midodrine with standard diuretic therapy in chronic liver disease patie

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with Chronic liver disease with refractory ascites. Patients above the age of 18 years. Patients of both gender Informed consent from the patient/ a legally authorised representative

Exclusion criteria

Exclusion criteria: noncirrhotic causes of ascites primary renal medical diseases, any grade of unresolved hepatic encephalopathy until it has improved and stabilized active gastrointestinal bleeding, Hepato-renal syndrome, previous antibiotic prophylaxis for spontaneous bacterial peritonitis, the presence of hepatocellular carcinoma and portal vein thrombosis active cardiovascular disease, systemic hypertension drugs that affect systemic and renal hemodynamic active alcohol consumption

Design outcomes

Primary

MeasureTime frame
To Access whether adding Rifaximin and midodrine to standard diuretic therapy Enhances diuresis and control of ascites with subsequent weight loss in patients with refractory ascitesTimepoint: 12 WEEKS—

Secondary

MeasureTime frame
To access the improvement in renal function and development of drug related side affects after adding adding Rifaximin and midodrine to standardTimepoint: 90 days—

Countries

India

Contacts

Public ContactDr ASHWIN PAUL

JSS MEDICAL COLLEGE HOSPITAL

drdeepaksuvarna@gmail.com9964380249

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026